Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 10/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 10/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408884 | 1.00 | HCRTR1 (0.42) | HCRTR1HCRTR2IDH1TP53FABP4 | |
| SCHEMBL2595526 | 0.85 | HCRTR1 (0.40) | HCRTR1HCRTR2FABP4FABP5KDM4E | |
| SCHEMBL408844 | 0.84 | HCRTR1 (0.44) | HCRTR1HCRTR2IDH1FABP4FABP5 | |
| SCHEMBL438019 | 0.84 | HCRTR1 (0.44) | HCRTR1HCRTR2IDH1FABP4FABP5 | |
| SCHEMBL2596218 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2IDH1TP53FABP4 | |
| SCHEMBL12299867 | 0.82 | HCRTR1 (0.43) | HCRTR1HCRTR2IDH1NR1H4 | |
| SCHEMBL2576712 | 0.81 | CCR5 (0.40) | TP53FABP4FABP5ADORA1 | |
| SCHEMBL2576715 | 0.81 | CCR5 (0.40) | TP53FABP4FABP5ADORA1 | |
| SCHEMBL19189826 | 0.80 | ADORA1 (0.36) | TP53FABP4FABP5ADORA1 | |
| SCHEMBL440762 | 0.77 | MTNR1A (0.41) | HCRTR1HCRTR2IDH1ADORA1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | HCRTR1 1535/4885HCRTR2 1110/4885IDH1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.